Inventiva (IVA) News Today $2.11 -0.08 (-3.65%) (As of 09/19/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Inventiva (IVA) Set to Announce Quarterly Earnings on WednesdaySeptember 18 at 1:01 AM | americanbankingnews.comInventiva (NASDAQ:IVA) Trading Down 5.2%Inventiva (NASDAQ:IVA) Stock Price Down 5.2%August 31, 2024 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)August 15, 2024 | markets.businessinsider.comINVENTIVA: Inventiva Reports Preliminary 2024 First-Half Financial InformationAugust 1, 2024 | finanznachrichten.deInventiva Reports Preliminary 2024 First-Half Financial Information¹July 31, 2024 | globenewswire.comINVENTIVA: Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25, 2024 | finanznachrichten.deInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25, 2024 | globenewswire.comINVENTIVA: Inventiva announces a €20.1 million issuance of royalty certificatesJuly 19, 2024 | finanznachrichten.deHalf-Year Review of Inventiva's Liquidity Contract with Kepler CheuvreuxJuly 19, 2024 | globenewswire.comInventiva announces a €20.1 million issuance of royalty certificatesJuly 18, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Sees Large Growth in Short InterestInventiva S.A. (NASDAQ:IVA - Get Free Report) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 130,800 shares, an increase of 12.6% from the June 15th total of 116,200 shares. Based on an average daily trading volume, of 15,000 shares, the days-to-cover ratio is currently 8.7 days.July 17, 2024 | marketbeat.comInventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial positionJuly 5, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Given Average Recommendation of "Buy" by AnalystsInventiva S.A. (NASDAQ:IVA - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers tJuly 3, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Short Interest Up 68.9% in JuneInventiva S.A. (NASDAQ:IVA - Get Free Report) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 116,200 shares, a growth of 68.9% from the May 31st total of 68,800 shares. Based on an average trading volume of 19,200 shares, the days-to-cover ratio is presently 6.1 days.June 30, 2024 | marketbeat.comResults of the votes of the Combined Shareholders' General Meeting of June 20, 2024June 21, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Receives Average Recommendation of "Buy" from AnalystsInventiva S.A. (NASDAQ:IVA - Get Free Report) has been given an average rating of "Buy" by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokJune 8, 2024 | marketbeat.comInventiva (NASDAQ:IVA) Stock Price Down 5.1%Inventiva (NASDAQ:IVA) Stock Price Down 5.1%June 5, 2024 | marketbeat.comCombined General Meeting of June 20, 2024 - Availability of the preparatory documentsMay 30, 2024 | globenewswire.comAltimmune: A Potential Minor Player In The Massive GLP-1 SpaceMay 28, 2024 | seekingalpha.comINVENTIVA: Inventiva announces two scientific presentations at the EASL International Liver Congress 2024May 22, 2024 | finanznachrichten.deInventiva announces two scientific presentations at the EASL International Liver Congress™ 2024May 22, 2024 | globenewswire.comINVENTIVA: Inventiva reports 2024 First Quarter Financial Information and provides a corporate updateMay 22, 2024 | finanznachrichten.deInventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateMay 21, 2024 | globenewswire.comInventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASHMay 16, 2024 | globenewswire.comFull Video Coverage: Investor Engagement in Private vs. Public Markets Panel From IPO Edge Bootcamp at NasdaqMay 14, 2024 | finance.yahoo.comInventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorMay 13, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Short Interest UpdateInventiva S.A. (NASDAQ:IVA - Get Free Report) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 77,700 shares, a growth of 34.9% from the March 31st total of 57,600 shares. Based on an average trading volume of 39,500 shares, the short-interest ratio is currently 2.0 days.April 28, 2024 | marketbeat.comInventiva S.A. ADRApril 26, 2024 | wsj.comHepion ends Phase 2 study for NASH drug due to cash restraintsApril 19, 2024 | msn.comCanaccord Genuity Group Increases Inventiva (NASDAQ:IVA) Price Target to $20.00Canaccord Genuity Group lifted their price objective on shares of Inventiva from $12.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday.April 8, 2024 | marketbeat.comInventiva S.A. Expected to Earn FY2025 Earnings of ($2.92) Per Share (NASDAQ:IVA)Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities researchers at HC Wainwright upped their FY2025 EPS estimates for Inventiva in a research note issued on Monday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will earn ($2.92) per share for the year, up from their preApril 4, 2024 | marketbeat.comInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-FApril 3, 2024 | globenewswire.comHC Wainwright Analysts Increase Earnings Estimates for Inventiva S.A. (NASDAQ:IVA)Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities research analysts at HC Wainwright boosted their FY2028 EPS estimates for Inventiva in a report released on Monday, April 1st. HC Wainwright analyst E. Arce now anticipates that the company will earn $2.45 per share for the year, up from theirApril 3, 2024 | marketbeat.comJulianne Moore y Nicholas Galitzine buscan seducir a un rey en “Mary & George”April 1, 2024 | msn.comBuy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical TrialsApril 1, 2024 | markets.businessinsider.comInventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call TranscriptApril 1, 2024 | finance.yahoo.comInventiva (NASDAQ:IVA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Inventiva in a research report on Monday.April 1, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)March 28, 2024 | markets.businessinsider.comINVENTIVA: Inventiva announces the nomination of Andre Turenne as DirectorMarch 28, 2024 | finanznachrichten.deInventiva announces the nomination of Andre Turenne as DirectorMarch 28, 2024 | globenewswire.comINVENTIVA: Inventiva reports its 2023 full-year resultsMarch 27, 2024 | finanznachrichten.deInventiva reports its 2023 full-year resultsMarch 27, 2024 | globenewswire.comInventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial ResultsMarch 22, 2024 | globenewswire.comPromising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH TreatmentMarch 21, 2024 | markets.businessinsider.comInventiva (NASDAQ:IVA) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $22.00 price objective on shares of Inventiva in a research note on Wednesday.March 20, 2024 | marketbeat.comInventiva (IVA) to Release Quarterly Earnings on WednesdayInventiva (NASDAQ:IVA) will be releasing earnings after the market closes on Wednesday, March 27, Zacks reports.March 20, 2024 | marketbeat.comPRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA ApprovalMarch 18, 2024 | markets.businessinsider.comInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2DMarch 18, 2024 | globenewswire.comMadrigal: Accelerated Rezdiffra Approval Puts It In The NASH LeadMarch 18, 2024 | seekingalpha.comShares of Madrigal Pharmaceuticals soar on FDA approval for NASH treatmentMarch 14, 2024 | bizjournals.com Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address “I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (Ad)Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now. Go here for the full details now. IVA Media Mentions By Week IVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVA News Sentiment▼0.310.44▲Average Medical News Sentiment IVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVA Articles This Week▼11▲IVA Articles Average Week Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FATE News Today VERV News Today SAGE News Today TSHA News Today KALV News Today CCCC News Today ITOS News Today AQST News Today LRMR News Today SLRN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVA) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | SponsoredThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free iva Stock Alerts